Design and Synthesis of mGlu2 NAMs with Improved Potency and CNS Penetration Based on a Truncated Picolinamide Core

Katrina A. Bollinger, Andrew S. Felts, Christopher J. Brassard, Julie L. Engers, Alice L. Rodriguez, Rebecca L. Weiner, Hyekyung P. Cho, Sichen Chang, Michael Bubser, Carrie K. Jones, Anna L. Blobaum, Colleen M. Niswender, P. Jeffrey Conn, Kyle Allen Emmitte, Craig W. Lindsley

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Herein, we detail the optimization of the mGlu2 negative allosteric modulator (NAM), VU6001192, by a reductionist approach to afford a novel, simplified mGlu2 NAM scaffold. This new chemotype not only affords potent and selective mGlu2 inhibition, as exemplified by VU6001966 (mGlu2 IC50 = 78 nM, mGlu3 IC50 > 30 μM), but also excellent central nervous system (CNS) penetration (Kp = 1.9, Kp,uu = 0.78), a feature devoid in all previously disclosed mGlu2 NAMs (Kps ≈ 0.3, Kp,uus ≈ 0.1). Moreover, this series, based on overall properties, represents an exciting lead series for potential mGlu2 PET tracer development.

Original languageEnglish
Pages (from-to)919-924
Number of pages6
JournalACS Medicinal Chemistry Letters
Volume8
Issue number9
DOIs
StatePublished - 1 Jan 2017

Fingerprint

Neurology
Modulators
Inhibitory Concentration 50
Central Nervous System
Scaffolds
picolinamide
Lead
VU6001192

Keywords

  • CNS penetration
  • Negative allosteric modulator (NAM)
  • VU6001966
  • depression
  • metabotropic glutamate receptor 2 (mGlu)

Cite this

Bollinger, K. A., Felts, A. S., Brassard, C. J., Engers, J. L., Rodriguez, A. L., Weiner, R. L., ... Lindsley, C. W. (2017). Design and Synthesis of mGlu2 NAMs with Improved Potency and CNS Penetration Based on a Truncated Picolinamide Core. ACS Medicinal Chemistry Letters, 8(9), 919-924. https://doi.org/10.1021/acsmedchemlett.7b00279
Bollinger, Katrina A. ; Felts, Andrew S. ; Brassard, Christopher J. ; Engers, Julie L. ; Rodriguez, Alice L. ; Weiner, Rebecca L. ; Cho, Hyekyung P. ; Chang, Sichen ; Bubser, Michael ; Jones, Carrie K. ; Blobaum, Anna L. ; Niswender, Colleen M. ; Conn, P. Jeffrey ; Emmitte, Kyle Allen ; Lindsley, Craig W. / Design and Synthesis of mGlu2 NAMs with Improved Potency and CNS Penetration Based on a Truncated Picolinamide Core. In: ACS Medicinal Chemistry Letters. 2017 ; Vol. 8, No. 9. pp. 919-924.
@article{f630420aabe5406ba94fa9227bcb0cc9,
title = "Design and Synthesis of mGlu2 NAMs with Improved Potency and CNS Penetration Based on a Truncated Picolinamide Core",
abstract = "Herein, we detail the optimization of the mGlu2 negative allosteric modulator (NAM), VU6001192, by a reductionist approach to afford a novel, simplified mGlu2 NAM scaffold. This new chemotype not only affords potent and selective mGlu2 inhibition, as exemplified by VU6001966 (mGlu2 IC50 = 78 nM, mGlu3 IC50 > 30 μM), but also excellent central nervous system (CNS) penetration (Kp = 1.9, Kp,uu = 0.78), a feature devoid in all previously disclosed mGlu2 NAMs (Kps ≈ 0.3, Kp,uus ≈ 0.1). Moreover, this series, based on overall properties, represents an exciting lead series for potential mGlu2 PET tracer development.",
keywords = "CNS penetration, Negative allosteric modulator (NAM), VU6001966, depression, metabotropic glutamate receptor 2 (mGlu)",
author = "Bollinger, {Katrina A.} and Felts, {Andrew S.} and Brassard, {Christopher J.} and Engers, {Julie L.} and Rodriguez, {Alice L.} and Weiner, {Rebecca L.} and Cho, {Hyekyung P.} and Sichen Chang and Michael Bubser and Jones, {Carrie K.} and Blobaum, {Anna L.} and Niswender, {Colleen M.} and Conn, {P. Jeffrey} and Emmitte, {Kyle Allen} and Lindsley, {Craig W.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1021/acsmedchemlett.7b00279",
language = "English",
volume = "8",
pages = "919--924",
journal = "ACS Medicinal Chemistry Letters",
issn = "1948-5875",
publisher = "American Chemical Society",
number = "9",

}

Bollinger, KA, Felts, AS, Brassard, CJ, Engers, JL, Rodriguez, AL, Weiner, RL, Cho, HP, Chang, S, Bubser, M, Jones, CK, Blobaum, AL, Niswender, CM, Conn, PJ, Emmitte, KA & Lindsley, CW 2017, 'Design and Synthesis of mGlu2 NAMs with Improved Potency and CNS Penetration Based on a Truncated Picolinamide Core', ACS Medicinal Chemistry Letters, vol. 8, no. 9, pp. 919-924. https://doi.org/10.1021/acsmedchemlett.7b00279

Design and Synthesis of mGlu2 NAMs with Improved Potency and CNS Penetration Based on a Truncated Picolinamide Core. / Bollinger, Katrina A.; Felts, Andrew S.; Brassard, Christopher J.; Engers, Julie L.; Rodriguez, Alice L.; Weiner, Rebecca L.; Cho, Hyekyung P.; Chang, Sichen; Bubser, Michael; Jones, Carrie K.; Blobaum, Anna L.; Niswender, Colleen M.; Conn, P. Jeffrey; Emmitte, Kyle Allen; Lindsley, Craig W.

In: ACS Medicinal Chemistry Letters, Vol. 8, No. 9, 01.01.2017, p. 919-924.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Design and Synthesis of mGlu2 NAMs with Improved Potency and CNS Penetration Based on a Truncated Picolinamide Core

AU - Bollinger, Katrina A.

AU - Felts, Andrew S.

AU - Brassard, Christopher J.

AU - Engers, Julie L.

AU - Rodriguez, Alice L.

AU - Weiner, Rebecca L.

AU - Cho, Hyekyung P.

AU - Chang, Sichen

AU - Bubser, Michael

AU - Jones, Carrie K.

AU - Blobaum, Anna L.

AU - Niswender, Colleen M.

AU - Conn, P. Jeffrey

AU - Emmitte, Kyle Allen

AU - Lindsley, Craig W.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Herein, we detail the optimization of the mGlu2 negative allosteric modulator (NAM), VU6001192, by a reductionist approach to afford a novel, simplified mGlu2 NAM scaffold. This new chemotype not only affords potent and selective mGlu2 inhibition, as exemplified by VU6001966 (mGlu2 IC50 = 78 nM, mGlu3 IC50 > 30 μM), but also excellent central nervous system (CNS) penetration (Kp = 1.9, Kp,uu = 0.78), a feature devoid in all previously disclosed mGlu2 NAMs (Kps ≈ 0.3, Kp,uus ≈ 0.1). Moreover, this series, based on overall properties, represents an exciting lead series for potential mGlu2 PET tracer development.

AB - Herein, we detail the optimization of the mGlu2 negative allosteric modulator (NAM), VU6001192, by a reductionist approach to afford a novel, simplified mGlu2 NAM scaffold. This new chemotype not only affords potent and selective mGlu2 inhibition, as exemplified by VU6001966 (mGlu2 IC50 = 78 nM, mGlu3 IC50 > 30 μM), but also excellent central nervous system (CNS) penetration (Kp = 1.9, Kp,uu = 0.78), a feature devoid in all previously disclosed mGlu2 NAMs (Kps ≈ 0.3, Kp,uus ≈ 0.1). Moreover, this series, based on overall properties, represents an exciting lead series for potential mGlu2 PET tracer development.

KW - CNS penetration

KW - Negative allosteric modulator (NAM)

KW - VU6001966

KW - depression

KW - metabotropic glutamate receptor 2 (mGlu)

UR - http://www.scopus.com/inward/record.url?scp=85029486744&partnerID=8YFLogxK

U2 - 10.1021/acsmedchemlett.7b00279

DO - 10.1021/acsmedchemlett.7b00279

M3 - Article

AN - SCOPUS:85029486744

VL - 8

SP - 919

EP - 924

JO - ACS Medicinal Chemistry Letters

JF - ACS Medicinal Chemistry Letters

SN - 1948-5875

IS - 9

ER -